key: cord-0940281-4bkqky2a
authors: Harzallah, Inès; Debliquis, Agathe; Drénou, Bernard
title: Lupus anticoagulant is frequent in patients with Covid‐19: Response to Reply
date: 2020-06-30
journal: J Thromb Haemost
DOI: 10.1111/jth.14980
sha: 6ad1bfabd6c8ef302d0f488ec02431a2efe65481
doc_id: 940281
cord_uid: 4bkqky2a

We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid‐19 patients (1). Different authors had confirmed these results (2). Connell and colleagues had discussed, in the Journal, technical points concerning LAC as well as anti‐phospholipids (aPL) auto‐antibodies detection (3).

We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (1) .

Different authors had confirmed these results (2) . Connell and colleagues had discussed, in the Journal, technical points concerning LAC as well as antiphospholipids (aPL) auto-antibodies detection (3) .

False positive LAC testing might be expected given the marked elevation in Creactive protein (CRP) levels seen in patients with Covid-19 since CRP has high affinity for phospholipids, especially phosphatidylcholine (4). As referred by Connell, the result of diluted Russell's viper venom time (dRVTT) test is not influenced whatever the rate of CRP (4). In our cohort of patients, LAC analysis has been performed as recommended by ISTH (5) with two tests: dRVTT first (Hemosil dRVTT Werfen) followed by sensitive aPTT based assays using Hemosil Silica Clotting Time Screen/Confirm (Werfen). All patients included in our series had positive dRVVT test which means that our results were not influenced by CRP.

By contrast with high frequency of LAC, we and others did not observe that the detection of anti-cardiolipin (aCL) or anti-β2-glycoprotein I (aβ2GPI) antibodies was common in Covid-19 patients and we had never discussed an antiphospholipid syndrome (2) . In a specific analysis Galeano-Valle had detected only 2 out of 24 patients positive for IgM aCL or aβ2GPI antibodies whereas IgG were negative (6).

LAC could participate to induce a hypercoagulable state. However, the relationship between the presence of LAC and thrombosis should be confirmed in large clinical series which is not available at present time. We are not able to confirm this correlation, since patients included in our series were critically ill and were all on curative dose of anticoagulation treatment. LAC could also reflect the presence of an This article is protected by copyright. All rights reserved Accepted Article autoimmune state. Thus, autoimmune clinical findings such as immune thrombocytopenia (7), autoimmune anemia or both are frequent and anti-nuclear antibodies seem to be detected with a high frequency (8) . 

Lupus anticoagulant is frequent in patients with Covid-19

Frequency of lupus anticoagulant in Covid-19 patients

Coagulopathy of COVID-19 and antiphospholipid antibodies

Lupus Anticoagulant (LAC) testing in patients with inflammatory status: Does C-reactive protein interfere with LAC test results?

Update of the guidelines for lupus anticoagulant detection

Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism

Haemophagocytosis in bone marrow aspirates in patients with COVID-19

High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia

Traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalise avec Covid-19 et surveillance de l

COVID-19 and its implications for thrombosis and anticoagulation